Hikma Pharmaceuticals PLC (LON:HIK)
London · Delayed Price · Currency is GBP · Price in GBX 1,636.00
+12.00 (0.74%)
Aug 21, 2026, 4:35 PM GMT
Hikma Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Hikma Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of 1,873p. The average 1-year stock price forecast is 14.52% higher than the current stock price, while the lowest is 1,306p (-20.18%) and the highest is 2,591p (+58.38%).
Price Target: 1,873p (+14.52%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Hikma Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 8 | 8 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 11 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Reiterates 1,700p → 1,870p | Buy | Reiterates | 1,700p → 1,870p | +14.30% | Aug 12, 2026 |
| Berenberg Bank | Berenberg Bank | Buy Reiterates 1,800p → 2,100p | Buy | Reiterates | 1,800p → 2,100p | +28.36% | Aug 11, 2026 |
| Deutsche Bank | Deutsche Bank | Buy Reiterates 1,950p | Buy | Reiterates | 1,950p | +19.19% | Aug 7, 2026 |
| Barclays | Barclays | Sell Maintains 1,350p | Sell | Maintains | 1,350p | -17.48% | Jun 23, 2026 |
| Jefferies | Jefferies | Buy Reiterates 1,850p → 1,870p | Buy | Reiterates | 1,850p → 1,870p | +14.30% | May 5, 2026 |
Financial Forecast
Revenue This Year
3.46B
from 3.35B
Increased by 3.40%
Revenue Next Year
3.61B
from 3.46B
Increased by 4.21%
EPS This Year
2.28
from 2.26
Increased by 0.74%
EPS Next Year
2.49
from 2.28
Increased by 9.53%
EPS and Forward PE are based on non-GAAP adjusted numbers.